This "Ocular Hypertension - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence Ocular Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Ocular Hypertension.
Ocular Hypertension Emerging Drugs Chapters
This segment of the Ocular Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ocular Hypertension Emerging Drugs
NCX 470: Nicox
NCX 470 is a new chemical entity formulated as an ophthalmic solution of this novel, second generation nitric oxide (NO)-donating prostaglandin analog in development for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. NCX 470 is designed to release both bimatoprost and NO following instillation into the eye. Currently, the drug is in phase 3 of development for the treatment of Ocular hypertension.
AGN 193408: AbbVie
AGN-190584 is an investigational optimized formulation of pilocarpine, a cholinergic muscarinic receptor agonist, which activates muscarinic receptors located at smooth muscles such as the iris sphincter muscle and ciliary muscle and is being investigated for the treatment of presbyopia as a topical, once-daily drop delivered by a proprietary vehicle. The proposed mechanism of action of AGN-190584 is through contraction of the iris sphincter muscle, constricting the pupil to enhance the depth of focus and improve near and intermediate visual acuity while maintaining some pupillary response to light. AGN-190584 also contracts the ciliary muscle, facilitating accommodation. The drug is currently in phase I/II of clinical trials for the treatment of Ocular hypertension.
Sepetaprost DE-126: Santen Pharmaceutical
A prostaglandin analogue eye drop drug product with a novel mode of action that is a dual agonist for both FP and EP3 receptors for the treatment of glaucoma and ocular hypertension. Started an additional Phase 2 in December 2020 in the U.S. Phase 2b completed in Japan.
Ocular Hypertension: Therapeutic Assessment
This segment of the report provides insights about the different Ocular Hypertension drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Ocular Hypertension
There are approx. 10+ key companies which are developing the therapies for Ocular Hypertension. The companies which have their Ocular Hypertension drug candidates in the most advanced stage, i.e. phase III include, Nicox.
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Ocular Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Ocular Hypertension: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ocular Hypertension therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Hypertension drugs.
Ocular Hypertension Report Insights
- Ocular Hypertension Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Ocular Hypertension Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Ocular Hypertension drugs?
- How many Ocular Hypertension drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ocular Hypertension?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ocular Hypertension therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ocular Hypertension and their status?
- What are the key designations that have been granted to the emerging drugs?
- Santen Pharmaceutical
- MediPrint Ophthalmics
- Whitecap Biosciences
- Ocular Therapeutix
- Chong Kun Dang Pharmaceutical
- Aerpio Pharmaceuticals
- NCX 470
- Sepetaprost DE-126
- AGN 193408
- Travoprost ophthalmic
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/pr117h